, Health and Social Care Committee
European models of health and social care: evidence session with academics
Thank you. So, we've had a discussion—. Sorry, first of all, thank you, both, for being here today; it's wonderful to be able to pick your brains about this. So, we've talked about how much funding there is, but I'd like to look a little bit more at how that…
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Of course. Thank you. That's really positive to hear. Thank you very much. Thank you, Chair.
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Okay. Is there anything you'd say specifically, then, about the gynaecological cancer clinical trials that you expect to see or are happening in Wales?
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Of course. Okay, thank you. Just my last question, then, more around the clinical trials: is expanding Wales's research capacity and providing a supporting infrastructure for cancer research and clinical trials a priority for the Welsh Government, and are you…
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Okay. And could you just give us an example that you have, especially if it's in relation to gynaecological cancer, where this may be something that's being delayed?
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
That's right. One moment—sorry. The main question I think we needed to ask on this was that Sarah Burton told the committee that some new cancer drugs and treatments had taken longer to introduce in Wales than in other parts of the UK because the funding…
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Just to double-check, we're on section 8, aren't we?
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
It's not me, is it?
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Okay. Thank you very much. Thank you, Chair.
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Right, okay. My last question. Again, the Wales Cancer Intelligence and Surveillance Unit's population-based cancer registry official statistics demonstrate that one-year survival has been decreasing slowly in Wales for uterine and ovarian cancers since…
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
And do you have a timescale for that?
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Absolutely.
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Okay. Because aren't you worried? It's 2019 that's the last—
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
So, when you ask them, 'Why haven't you done it?', what do they tell you?
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Brilliant. Thank you. And then the most recent data on cancer incidence and survival covers the period 2017 to 2019, which really does limit its usefulness, especially as it was pre COVID and so much has changed, particularly with access to in-person…
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Could you write to us then, and follow up with us on that?
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
What are our targets, then, for survival rates?
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
No, that's fine. I think the answers should be able to be given in that time, for sure. So, we've mentioned analysing data today, we've mentioned the comparison with the English NHS as well. So, I'm going to ask some questions now about the data and…
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Absolutely.
, Health and Social Care Committee
Gynaecological cancers: evidence session with the Minister for Health and Social Services
Yes. I just wanted to reinforce what you've said, Minister, because I've got constituents at the moment, but I've also got many friends and many women in my life, and this is very common to women out there. They will go to their GP with pain, their GP will…
, Plenary
Questions to the Minister for Health and Social Services
Diolch, Minister. It is good to hear that positive news about the potential as well for e-prescribing across Wales, because there are so many benefits to it, including not having millions of pieces of prescription paper flying around Wales all of the time…
, Plenary
Questions to the Minister for Health and Social Services
6. What work has the Welsh Government done to engage with vulnerable groups in relation to e-prescribing? OQ59923
, Plenary
Questions to the First Minister
Diolch, First Minister. Earlier this year, the UK Government published the integrated review refresh, called 'Responding to a more contested and volatile world', which highlighted its priorities for protecting the United Kingdom. It is clear from this report…
, Plenary
Questions to the First Minister
6. What steps is the Welsh Government taking to address online disinformation? OQ59944
, Equality and Social Justice Committee
The public health approach to preventing gender-based violence: evidence session 10
Thank you very much, and thank you, Chair.
